ArticleTransplant international : official journal of the European Society for Organ Transplantation2025
Multi-Center Outcome Analysis of 16 Face Transplantations - A Retrospective OPTN Study.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A systematic review of treatment strategies to combat acute and chronic rejection episodes in vascularized composite allotransplantation.Frontiers in immunology · 2026Pooled it
- What are the functional outcomes of total laryngeal transplantation? A systematic review of preclinical and clinical studies.Frontiers in immunology · 2025Pooled it
- Bio-boosting transplants: a systematic review on biopolymers in vascular composite allotransplantation.Frontiers in immunology · 2025Pooled it
- Vascularized composite xenotransplantation: Where we have been and where we could go?Cell transplantationPooled it
- Where Do We Stand for Nerve Regeneration and Functional Recovery After Vascularized Composite Allotransplantation?Microsurgery · 2026Review
- Transplant International: Looking Back at 2025, Looking Forward to 2026.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Clustering and predicting VCA patient populations - a machine learning approach into vascularized composite allotransplantation.Frontiers in immunology · 2026Article
- Rewiring faces: advances and outcomes in facial nerve reconstruction after facial vascularized composite allotransplantation.Frontiers in surgery · 2026Review
- CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.Cell reports. Medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facial Vascularized Composite Allotransplantation (fVCA) restores form and function for patients with severe facial disfigurements, yet multi-center outcome data remain scarce. We accessed the Organ Procurement and Transplantation Network (OPTN) database from 2008 to 2024 to identify all full- or partial-face fVCA recipients, excluding patients under 18 years and those with physiologically impossible BMIs. Of 25 identified patients, 16 (64%) met inclusion criteria (69% male; mean age 43 ± 14 years). Recipients experienced a median of 5 [IQR 0.0-10] acute rejection episodes, which correlated with inotrope use during donor procurement (p = 0.033). On average, patients were hospitalized 2.4 ± 1.8 times, with arginine vasopressin (AVP) administration linked to fewer hospitalizations (p = 0.035). Seven recipients (44%) experienced complications, and extended-criteria donor (ECD) status was associated with higher complication rates (p = 0.049). These findings underscore the promise of fVCA to address complex facial defects while identifying key risk factors-particularly inotrope use and ECD status, while AVP administration may mitigate hospital stays. Further studies with larger cohorts are warranted to refine perioperative strategies, improve outcomes, and expand the clinical utility of fVCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.